The Optonol company will present during the "ILSI-Biomed Israel 2008" week, the solution it developed against glaucoma, one of the common eye diseases that cause damage to the visual field and blindness * Many foreign delegations have assured Bowen
The Optonol company will present during the "ILSI-Biomed Israel 2008" week, the solution it developed against glaucoma, one of the common eye diseases that cause damage to the visual field and blindness, also called "the silent thief of sight". The development: an innovative drain, Ex-PRESSTM, which lowers the intraocular pressure to the desired level, immediately, and prevents the deterioration of the disease. Over 67 million people worldwide suffer from glaucoma. In the US, over 3 million people have glaucoma and 100,000 of them have gone blind because of the disease.
Glaucoma manifests itself in increased intraocular pressure that causes pressure on the optic nerve and leads slowly and painlessly to a reduction in the visual field and eventually to blindness. It is not possible to cure glaucoma or return the condition to its original state, rather, it is only possible to maintain the existing one by balancing the intraocular pressure with the help of drops, drugs, or surgery. For people who do not respond to drug treatment, the advanced surgery to implant the Ex-PRESSTM drain is possible.
The drain, developed by Optonol, is made of the same metal that stents for cardiological uses are made of, and is smaller than a grain of rice (<3mm) with an internal diameter of 50 or 200 microns. One end is sharp (to facilitate insertion into the eye), and at the other end is a disk (to prevent excessive penetration of the drain into the eye) and on its surface there is a stop whose purpose is to fix the drain in the eye. After implanting this tiny drain, the fluids drain from the front part of the eye into the eye tissue and thus the intraocular pressure drops to the desired level.
The Optonol company, located in Neve Ilan, specializes in the development of miniature products mainly for the field of optometry. It was established in 1996 by CEO Ira Yaron.
The set of commercial annexes of the Administration for Foreign Trade in the Ministry of Foreign Trade is mobilizing to promote Biomed 2008
Among the visitors coming to the event: a delegation from the Washington area, a delegation from the Los Angeles area, a delegation from Korea, a delegation from Singapore, representatives of companies from Canada, a delegation from Taiwan.
Boaz Hirsch, Deputy Director General of the TMT and Director of the Administration for Foreign Trade, explains: "The commercial annexes of the Foreign Trade Administration at the TMT work throughout the year to locate target companies for investment in Israel, to locate owners, distributors and representatives for the Israeli companies. The appendices focus on bringing representatives of these companies to the biomed event." The event will include professional lectures in various fields as well as a professional exhibition. Also this year, similar to last year's format, a world conference in the field of stem cells will be held at the same time."
"Last year, as a result of the promotional activity of the set of commercial attachments, hundreds of guests arrived from dozens of target companies around the world, in delegations and individually. Also this year, as a result of extensive operations by the set of commercial annexes to promote the biotechnology industry in general and the event in Israel in particular, hundreds of guests from abroad are expected to come to the event."
Among the visitors coming to Israel:
- A delegation from the Washington region, led by the governor of Maryland, organized by the commercial attaché of the Washington TMT, Ohad Cohen.
- A visit by a senior representative of the FDA, coordinated by the commercial attaché of the Washington TMT, Ohad Cohen. The purpose of the visit is to present the methods of FDA activity to Israeli companies and to increase their understanding of the work processes with the organization.
- A delegation from the Los Angeles area consisting of representatives of about ten companies in the field of medical equipment and biotechnology. The expedition is organized by the commercial annex of the TMT in Los Angeles, Shay Eisen.
- A delegation from Korea numbering about forty companies including a bunch of pharma, biotechnology and medical equipment. The expedition is organized by Alon Schlesinger, the commercial annex of the TMT in Korea (see news below)
- A delegation from Singapore consisting of representatives of about ten companies organized by the commercial branch of the Anat Katz TMT. The Singaporean companies arriving in the delegation are mostly engaged in the field of fine robotics.
- Representatives of companies from Canada organized by the commercial annex of the Ministry of Trade and Industry in Toronto, Yonatan Levy. In this mission, it should be noted the arrival of a representative of the great Mount Sinai Hospital who will arrive for the purpose of locating Israeli products and technologies.
- A delegation from Taiwan numbering about ten representatives organized by the commercial annex of the Hovav Raf Ministry of Tourism. The delegation consists mainly of representatives of leading academic institutions interested in cooperation with Israeli research and academic institutions.
Boaz Hirsch, Deputy Director General of the TMT and Director of the Administration for Foreign Trade, points out that in recent years the field of life sciences has been favored in the activity of commercial annexes in relevant markets.
Hirsch also points out that the commercial annexes of the Foreign Trade Administration in TMT, in the countries defined as target countries, are working throughout the year to locate target companies for investment in Israel, to locate owners, distributors and representatives for the Israeli companies. The appendices focus on bringing representatives of these companies to the biomed event.
The Administration for Foreign Trade at the Ministry of Foreign Affairs reported that in 2007 Israeli companies exported over $5.3 billion in medical equipment and pharmaceuticals, an amount that is about 15% of all industrial exports that year. Inaccurate data. The main target markets for Israeli exports in this area are North America, Europe and the Far East.
A Korean biotechnology delegation will visit Israel and participate in the Biomed 2008 exhibition
A delegation of Korean biotechnology and pharmaceutical companies will arrive in Israel for the Biomed 2008 exhibition, which will be held in Tel Aviv on May 27-29, 2008. The Korean delegation consists of approximately forty representatives of companies in Korea in the fields of biotechnology, pharma, medical equipment and research. This is the fifth year in a row that a delegation from South Korea has come to take part in the exhibition, and this is thanks to the efforts of the commercial annex of the TMT in Seoul.
Leading companies that will contact the delegation are: Hanmi Company, SK Chemicals, representatives of the 2 leading hospitals and universities in Korea Hospital SNU and Yonsei Hospital, DongAh Pharmaceutical, and Kolon Pharm.
In addition, the delegation will be joined by representatives from the WONJU districts, well-known in the medical industry. Also, representatives of the Jeolla Namdo district will arrive in Israel to promote relations in the medical field with Israel.
As part of the visit, a cooperation agreement will be signed between the representatives of the WONJU district Wonju Medical Industry Techno Valley and the export institute.
During the visit, the Korean companies will hold a series of personal meetings with Israeli companies coordinated by the commercial delegation of the Administration for Foreign Trade in Seoul in cooperation with the Export Institute, and they will also visit the exhibition and participate in various lectures. In addition, the delegation will hold a professional tour.
The commercial attaché of the Ministry of Foreign Affairs and Trade in Korea, Alon Schlesinger, states that the life sciences branch is a branch promoted as a top priority by the economic annexation in Korea in recent years and that the Korean delegations coming to Biomed are increasing year by year and are a center of attraction for leading companies in the field of life sciences in Korea.
The commercial affiliate in Korea focuses on building a set of local connections that will enable proper penetration of Israeli companies into the local market, which has unique behavior patterns, as well as activity to promote investments in the field of pharmaceuticals in Israel.
Korea has set the promotion of the biotechnology industry as a national goal and the potential for cooperation between the countries is high. The giant companies in Korea have high financial capabilities, access to large markets and are looking for new technologies. In Korea, a country with a population of about 50 million people, there are about 550 biotechnology companies, while in Israel, with a population of about 7 million people, there are over 900 biotechnology companies. In Korea there is a growing demand for the most advanced medical services in the world. The country has a particularly high percentage of an aging population together with accelerated economic development and a culture of adopting innovations and high technological developments. Israeli industry has many technologies to offer in the biotechnology industry and in Korea there is a high regard for research institutions and companies from Israel.
From the Administration for Foreign Trade in the Ministry of Foreign Affairs, which is the body entrusted with the promotion of Israeli exports and the development of business opportunities, among other things, by economic attachés in the countries of their mandate, it was stated that Dr. Korea is defined as a 'target country for Israeli exports' and for this purpose, many resources are allocated to encourage exports to the country in the fields chosen One of these fields is the field of medical equipment and pharmaceuticals.
In the first quarter of 2008, the volume of trade between Israel and Korea amounted to 533 million dollars. Israeli exports to Korea amounted to 231 million dollars. Imports from Korea are $302 million. The bulk of Israeli exports to Dr. Korea consists of exports of the high-tech and communications industry, which make up over 50% of the exports, at the same time, about 40% of the imports from Korea are in the field of consumer goods and electrical devices imported from the country and another 20% are imports of the automobile industry.
